Cargando…

SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease

Background: Urinary symptoms are common, disabling and generally unresponsive to treatment in Parkinson´s disease (PD). Safinamide is approved as an add-on therapy to levodopa to improve fluctuations. Methods: Retrospective analysis of electronic records of nondemented PD patients seen consecutively...

Descripción completa

Detalles Bibliográficos
Autores principales: Gómez-López, Ana, Sánchez-Sánchez, Arantxa, Natera-Villalba, Elena, Ros-Castelló, Victoria, Beltrán-Corbellini, Álvaro, Fanjul-Arbós, Samira, Pareés Moreno, Isabel, López-Sendon Moreno, José Luis, Martínez Castrillo, Juan Carlos, Alonso-Canovas, Araceli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825064/
https://www.ncbi.nlm.nih.gov/pubmed/33418858
http://dx.doi.org/10.3390/brainsci11010057
_version_ 1783640223027036160
author Gómez-López, Ana
Sánchez-Sánchez, Arantxa
Natera-Villalba, Elena
Ros-Castelló, Victoria
Beltrán-Corbellini, Álvaro
Fanjul-Arbós, Samira
Pareés Moreno, Isabel
López-Sendon Moreno, José Luis
Martínez Castrillo, Juan Carlos
Alonso-Canovas, Araceli
author_facet Gómez-López, Ana
Sánchez-Sánchez, Arantxa
Natera-Villalba, Elena
Ros-Castelló, Victoria
Beltrán-Corbellini, Álvaro
Fanjul-Arbós, Samira
Pareés Moreno, Isabel
López-Sendon Moreno, José Luis
Martínez Castrillo, Juan Carlos
Alonso-Canovas, Araceli
author_sort Gómez-López, Ana
collection PubMed
description Background: Urinary symptoms are common, disabling and generally unresponsive to treatment in Parkinson´s disease (PD). Safinamide is approved as an add-on therapy to levodopa to improve fluctuations. Methods: Retrospective analysis of electronic records of nondemented PD patients seen consecutively in a Movement Disorders Unit (November 2018–February 2019). All were assessed with Scale for Outcomes in Parkinson’s disease for Autonomic Symptoms-Urinary subscale (SCOPA-AUT-U) by the attending neurologist, and a month afterwards by an independent researcher blinded to treatment and clinical records in a routine clinical practice setting. Clinical variables were compared among patients who were prescribed safinamide (SA+) for the treatment of motor fluctuations and those with different treatment regimes (SA−). Results: From 169 patients screened initially, 54 were excluded due to severe incontinence, absence of urinary symptoms or previous safinamide treatment. Thirty-five patients were included in SA+ and 79 in SA−. Both groups were comparable in terms of clinical variables, except in basal urinary symptoms, with more severity in the SA+ group. In the follow-up assessment, total SCOPA-AUT-U, as well as urgency, incontinence, frequency and nocturia subscales improved significantly in the SA+ group, while the SA− group remained unchanged. Conclusions: Safinamide could be helpful in the improvement of urinary symptoms in PD.
format Online
Article
Text
id pubmed-7825064
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78250642021-01-24 SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease Gómez-López, Ana Sánchez-Sánchez, Arantxa Natera-Villalba, Elena Ros-Castelló, Victoria Beltrán-Corbellini, Álvaro Fanjul-Arbós, Samira Pareés Moreno, Isabel López-Sendon Moreno, José Luis Martínez Castrillo, Juan Carlos Alonso-Canovas, Araceli Brain Sci Article Background: Urinary symptoms are common, disabling and generally unresponsive to treatment in Parkinson´s disease (PD). Safinamide is approved as an add-on therapy to levodopa to improve fluctuations. Methods: Retrospective analysis of electronic records of nondemented PD patients seen consecutively in a Movement Disorders Unit (November 2018–February 2019). All were assessed with Scale for Outcomes in Parkinson’s disease for Autonomic Symptoms-Urinary subscale (SCOPA-AUT-U) by the attending neurologist, and a month afterwards by an independent researcher blinded to treatment and clinical records in a routine clinical practice setting. Clinical variables were compared among patients who were prescribed safinamide (SA+) for the treatment of motor fluctuations and those with different treatment regimes (SA−). Results: From 169 patients screened initially, 54 were excluded due to severe incontinence, absence of urinary symptoms or previous safinamide treatment. Thirty-five patients were included in SA+ and 79 in SA−. Both groups were comparable in terms of clinical variables, except in basal urinary symptoms, with more severity in the SA+ group. In the follow-up assessment, total SCOPA-AUT-U, as well as urgency, incontinence, frequency and nocturia subscales improved significantly in the SA+ group, while the SA− group remained unchanged. Conclusions: Safinamide could be helpful in the improvement of urinary symptoms in PD. MDPI 2021-01-06 /pmc/articles/PMC7825064/ /pubmed/33418858 http://dx.doi.org/10.3390/brainsci11010057 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gómez-López, Ana
Sánchez-Sánchez, Arantxa
Natera-Villalba, Elena
Ros-Castelló, Victoria
Beltrán-Corbellini, Álvaro
Fanjul-Arbós, Samira
Pareés Moreno, Isabel
López-Sendon Moreno, José Luis
Martínez Castrillo, Juan Carlos
Alonso-Canovas, Araceli
SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease
title SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease
title_full SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease
title_fullStr SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease
title_full_unstemmed SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease
title_short SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease
title_sort surinpark: safinamide for urinary symptoms in parkinson’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825064/
https://www.ncbi.nlm.nih.gov/pubmed/33418858
http://dx.doi.org/10.3390/brainsci11010057
work_keys_str_mv AT gomezlopezana surinparksafinamideforurinarysymptomsinparkinsonsdisease
AT sanchezsanchezarantxa surinparksafinamideforurinarysymptomsinparkinsonsdisease
AT nateravillalbaelena surinparksafinamideforurinarysymptomsinparkinsonsdisease
AT roscastellovictoria surinparksafinamideforurinarysymptomsinparkinsonsdisease
AT beltrancorbellinialvaro surinparksafinamideforurinarysymptomsinparkinsonsdisease
AT fanjularbossamira surinparksafinamideforurinarysymptomsinparkinsonsdisease
AT pareesmorenoisabel surinparksafinamideforurinarysymptomsinparkinsonsdisease
AT lopezsendonmorenojoseluis surinparksafinamideforurinarysymptomsinparkinsonsdisease
AT martinezcastrillojuancarlos surinparksafinamideforurinarysymptomsinparkinsonsdisease
AT alonsocanovasaraceli surinparksafinamideforurinarysymptomsinparkinsonsdisease